v3.22.2.2
Inventory
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory
5. Inventory
Inventory consists of the following (in thousands):
 
 
  
September 30,
2022
 
  
December 31,
2021
 
Raw materials
   
$
17,807
 
    $ 2,484  
Work in process
   
 
1,987
 
      2,407  
Finished goods
   
 
3,803
 
      3,057  
    
 
 
     
 
 
  
    
$
23,597
 
    $ 7,948  
    
 
 
     
 
 
  
Product costs incurred prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development as incurred.